Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing

Sorafenib is the first-line therapeutic option for advanced hepatocellular carcinoma (HCC). Many patients exhibit a primary resistance (PR) response after initial treatment. In previous studies, compared to acquired resistance, the mechanism of PR is unclear. The present study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xin, Wu, Yi, Zhang, Shuqin, Liu, Zhiyi, Fan, Qingjie, Fang, Shuai, Qiao, Sennan, Sun, Fei, Liang, Chongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379008/
https://www.ncbi.nlm.nih.gov/pubmed/34421602
http://dx.doi.org/10.3389/fphar.2021.709343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379008/
https://www.ncbi.nlm.nih.gov/pubmed/34421602
http://dx.doi.org/10.3389/fphar.2021.709343

Ejemplares similares